cagrilintide retatrutide blend EZP-3P/EZP-CG – 12.5mg/2.5mg – Research-Grade Compound Cagrilintide – 10mg – Prime
Description
18 Tears are classified as acute when treated within three months from the time of injury
MINOR CLARIFICATIONS S0
Published trials used oral doses of 0.25 mg to 30 mg per day and intravenous single doses of 25 to 400 mcg/kg
This code is significant for managing injections that do not lie under particular process codes
